Business
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategyWALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken
About this update from Zenas Biopharma, Inc.
[{"type":"image","alt":"Zenas BioPharma","displaySize":"","headline":null,"caption":"Zenas BioPharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SnwQ6A_D0E0nzqSYhAWCEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/eefa06b05812fb9024bab85fc9c60cc1","width":300,"height":117}},"lazy":false},{"type":"text","content":"Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy","length":127,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development.","length":516,"tagName":"p"},{"type":"text","content":"“Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approvals for multiple products at global biopharmaceutical companies to create value and improve the lives of patients,” said Lisa von Moltke, M.D., Head of R&D and Chief Medical Officer of Zenas. “We are thrilled to have Haley join Zenas as we progress obexelimab through Phase 2 and Phase 3 clinical trials and pursue expansion of our pipeline through business development.”","length":564,"tagName":"p"},{"type":"text","content":"“I am pleased to join Zenas during such a milestone-rich year,” said Dr. Laken. “I am excited to collaborate with this accomplished team to advance obexelimab, a potentially differentiated B cell targeted therapy, to transform the lives of patients with IgG4-related disease, multiple sclerosis and systemic lupus erythematosus, as well as support expansion of the Zenas pipeline.”","length":381,"tagName":"p"},{"type":"text","content":"Prior to joining Zenas, Dr. Laken se...